Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
Abstract Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe3O4 nanoparticles radiolabeled with 68Ga,...
Guardado en:
Autores principales: | Maria-Argyro Karageorgou, Dimosthenis Stamopoulos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f9189ee69ced4cb9ba8b1377a0369d06 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma
por: Liang J, et al.
Publicado: (2017) -
A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging
por: Sun J, et al.
Publicado: (2019) -
Bombesin-functionalized superparamagnetic iron oxide nanoparticles for dual-modality MR/NIRFI in mouse models of breast cancer
por: Li L, et al.
Publicado: (2019) -
Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents
por: Estelrich J, et al.
Publicado: (2015) -
Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
por: Iancu SD, et al.
Publicado: (2020)